Evotec SE — M&A Activity 2014

Mar 24, 2014

News Details

Corporate | 24 March 2014 07:29

Evotec acquires Bionamics GmbH to accelerate ‘EVT Innovate’ strategy

DGAP-News: Evotec AG / Key word(s): Acquisition

24.03.2014 / 07:29

---

* Expanding discovery pipeline with portfolio of projects especially in
Multiple Sclerosis and CNS
* Appointment of Dr Timm Jessen as "EVP Business Development EVT Innovate"
to further enhance translation capabilities

Hamburg, Germany - 24 March 2014: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced the acquisition of the
Germany-based Bionamics GmbH. Bionamics is an asset management company that
focuses on the translation of academic innovations into attractive assets
for the biotech and Pharma industry. The transaction comprises the
acquisition of all shares of Bionamics against cash and future milestone
payments. Next to an experienced management team Bionamics brings a
portfolio of highly attractive and fully funded projects especially in
neurodegeneration and CNS to Evotec.

Further financial details of the transaction remain undisclosed.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "With the
acquisition of Bionamics we accelerate our EVT Innovate strategy and
enlarge our reach towards outstanding innovations. We welcome the openness
of Bionamics to join the discovery infrastructure of Evotec. We are also
very happy to welcome Dr Timm Jessen back at Evotec. In his new management
role, Dr Jessen will be responsible for the commercialisation of "EVT
Innovate" projects."

Dr Timm Jessen, Managing Director of Bionamics GmbH, commented: "We highly
value Evotec's strategic appreciation of our work and its success as
demonstrated e.g. in managing the NEU² programme, a consortium of academic,
biotech and Pharma partners focussing on novel products to treat Multiple
Sclerosis and other neurodegenerative diseases. The combination of our
management skills with Evotec's strong operational capabilities offers a
unique constellation for researchers and entrepreneurs around the globe to
accelerate their innovation together with us. I very much look forward to
expand this concept further within the Evotec Group."

ABOUT BIONAMICS
Bionamics GmbH is an asset management company in Hamburg, Germany, bridging
the gap between excellent research projects and the industry's need for
pre-clinical and clinical development programmes. The company was founded
in 2006 and currently employs three employees. Bionamics has set up and
manages NEU² (www.neu-quadrat.de), a consortium established to generate new
treatment options in neurodegenerative diseases and supported by public
funds of up to EUR 40 Mio. Before founding Bionamics Timm Jessen was the
CSO of Evotec AG from 1997 to 2004.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.

Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

End of Corporate News

---

24.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart

End of News DGAP News-Service

259009 24.03.2014